Economic burden of empiric drug utilization in metastatic renal cell carcinoma emphasizes the need for early biomarkers of response. Chen, V., Gong, C., Zhang, C. A., Srinivas, S., Lee, H. E., Fan, A. C. AMER SOC CLINICAL ONCOLOGY. 2017

View details for DOI 10.1200/JCO.2017.35.15_suppl.e16072

View details for Web of Science ID 000411931702162